Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market.

Key Points TRIUMPH-2 contains retatrutide, a triple agonist weight loss drug. Triple-agonist drugs attempt to suppress appetite, lower blood sugar, and increase calorie burn. Study participants with a body mass index over 35% who took a 12 milligram dose lost an average of 60.8 pounds over 80 weeks. 10 stocks we like better than Eli Lilly › A new weight-loss drug from Eli Lilly (NYSE:LLY) may reset the bar for treating obesity and helping adults with type 2 diabetes lower their blood sugar.